EDMONTON, AB, July 10, 2023 /CNW/ - Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company"), a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies announced that a U.S patent has been granted to its lead product candidate MAb AR 9.6 that will protect many isoforms of monoclonal antibody including IgE and its AllergoOncology Technology.
Read more at newswire.caQuest PharmaTech Provides Product Development Update
Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.
